TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study
Brief Summary: The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.


Options:
A: Arm Label: Vibegron + Placebo to match Tolterodine; Type: EXPERIMENTAL; Interventions: Drug: vibegron, Drug: Tolterodine placebo | Arm Label: Placebo to match vibegron + Placebo to match Tolterodine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine placebo | Arm Label: Tolterodine + Placebo to match vibegron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine Tartrate ER | Intervention Type: DRUG; Name: vibegron; Assigned to Arm(s): Vibegron + Placebo to match Tolterodine | Intervention Type: DRUG; Name: Vibegron placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine Tartrate ER; Assigned to Arm(s): Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Vibegron + Placebo to match Tolterodine
B: Arm Label: Oxybutynin topical gel; Type: EXPERIMENTAL; Interventions: Drug: Oxybutynin topical gel | Arm Label: Placebo topical gel; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo topical gel | Intervention Type: DRUG; Name: Oxybutynin topical gel; Assigned to Arm(s): Oxybutynin topical gel | Intervention Type: OTHER; Name: Placebo topical gel; Assigned to Arm(s): Placebo topical gel
C: Arm Label: Solifenacin; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin | Arm Label: Oxybutynin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Solifenacin; Assigned to Arm(s): Solifenacin | Intervention Type: DRUG; Name: Oxybutynin; Assigned to Arm(s): Oxybutynin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)
Brief Summary: Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.


Options:
A: Intervention Type: DEVICE; Name: Pulmonary function Testing; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): N/A
B: Arm Label: tiotropium 2.5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 1.25 mcg (2 actuations/day) | Arm Label: tiotropium 18 mcg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium 18 mcg | Arm Label: tiotropium 5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg (2 actuations/day) | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 1.25 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 2.5 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 5 mcg and placebo
C: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)
Brief Summary: Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.


Options:
A: Intervention Type: DRUG; Name: Tiotropium (Spiriva®); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
C: Arm Label: tiotropium 2.5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 1.25 mcg (2 actuations/day) | Arm Label: tiotropium 18 mcg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium 18 mcg | Arm Label: tiotropium 5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg (2 actuations/day) | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 1.25 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 2.5 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 5 mcg and placebo
D: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Antenatal Vitamin D Supplementation on Maternal-fetal Vitamin D Status and Neonatal Immune Function: a Randomized Controlled Trial in Bangladesh
Brief Summary: This study is a randomized placebo-controlled trial of oral weekly vitamin D3 (cholecalciferol) supplementation during the third trimester of pregnancy among women in Dhaka, Bangladesh. The overall goal of the study is to establish whether there is evidence that improving vitamin D status among pregnant women in Bangladesh will enhance the resistance of the infant offspring to infection.

The aims of the study are to assess the effect of supplementation on 1) maternal and infant vitamin D status (based on blood concentrations of a vitamin D metabolite) and, 2) markers of neonatal immune function.


Options:
A: Arm Label: Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo control | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo control; Assigned to Arm(s): Control
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: n-3 fatty acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: n-3 fatty acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: olive oil; Assigned to Arm(s): 2
C: Arm Label: 200 IU/day Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 400 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 600 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 800 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day; Assigned to Arm(s): 200 IU/day Vitamin D, 400 IU/day Vitamin D, 600 IU/day Vitamin D, 800 IU/day Vitamin D
D: Arm Label: Sustained; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Diet-Limited; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Diet-Limited | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Sustained

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)
Brief Summary: The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.


Options:
A: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glipizide | Arm Label: glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): glipizide
B: Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: BI 10773 X mg; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 | Arm Label: BI 10773 Y mg; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 Y mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 X mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
C: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo (oral) | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo (oral) | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Placebo (subcutaneous) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Placebo (oral); Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Placebo (subcutaneous); Assigned to Arm(s): Metformin
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin 10 MG | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Dapagliflozin 10 MG; Assigned to Arm(s): Dapagliflozin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized Controlled Trial to Promote Healthful Fish Consumption in Pregnancy
Brief Summary: The overall goal of this project is to establish a pilot study to develop and refine an intervention to promote consumption of fish low in mercury and high in n-3 PUFA among pregnant women. The investigators will demonstrate our ability to recruit pregnant women, influence their fish consumption, and measure changes in nutrient and toxicant biomarkers.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): 1, 2
B: Arm Label: DHA arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): DHA arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo arm
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA Supplements | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplements; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Supplements; Assigned to Arm(s): 2
D: Arm Label: Dietary advice and grocery store card; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary advice | Arm Label: Dietary advice; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary advice | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Dietary advice; Assigned to Arm(s): Dietary advice, Dietary advice and grocery store card | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: STUDIO IN DOPPIO CIECO DISODIOCROMOGLICATO + PLACEBO vs DISODIOCROMOGLICATO + IMMUNOTERAPIA SPECIFICA SUBLINGUALE PER ALTERNARIA IN PAZIENTI CON RINITE ALLERGICA DOVUTA A SENSIBILIZZAZIONE AD ALTERNARIA
Brief Summary: Respiratory allergy due to Alternaria is a relevant clinical problem, and specific immunotherapy may represent a viable treatment option. Sublingual immunotherapy (SLIT) is safe and effective, but data for Alternaria are lacking. The study is aimed at assessing the efficacy of a standardized SLIT in patients sensitised to Alternaria, in a randomized, double blind, placebo controlled fashion.

Patients with rhinitis with/without intermittent asthma, and ascertained allergy to Alternaria are enrolled. After a baseline season, SLIT or matched placebo are given for 10 months. Symptoms and rescue medication intake are recorded on diary cards from June to October. Skin prick test, specific IgE and IgG4 and precipitins are measured at baseline and at the end of the study. Alternaria spore count is also performed. Primary outcome is the change in symptom score in the active vs placebo group. Secondary outcomes: changes in rescue medication intake, alternaria specific IgE and IgG4, skin prick test reactivity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Immunotherapy; Type: EXPERIMENTAL; Interventions: Biological: Grass pollen allergens in a water/glycerol solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Grass pollen allergens in a water/glycerol solution; Assigned to Arm(s): Immunotherapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: SLIT; Type: EXPERIMENTAL; Interventions: Biological: sublingual immunotherapy | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: sublingual immunotherapy; Assigned to Arm(s): SLIT | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Birch pollen allergen extract; Type: EXPERIMENTAL; Interventions: Biological: Birch pollen allergen extract | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Birch pollen allergen extract; Assigned to Arm(s): Birch pollen allergen extract

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: STUDIO IN DOPPIO CIECO DISODIOCROMOGLICATO + PLACEBO vs DISODIOCROMOGLICATO + IMMUNOTERAPIA SPECIFICA SUBLINGUALE PER ALTERNARIA IN PAZIENTI CON RINITE ALLERGICA DOVUTA A SENSIBILIZZAZIONE AD ALTERNARIA
Brief Summary: Respiratory allergy due to Alternaria is a relevant clinical problem, and specific immunotherapy may represent a viable treatment option. Sublingual immunotherapy (SLIT) is safe and effective, but data for Alternaria are lacking. The study is aimed at assessing the efficacy of a standardized SLIT in patients sensitised to Alternaria, in a randomized, double blind, placebo controlled fashion.

Patients with rhinitis with/without intermittent asthma, and ascertained allergy to Alternaria are enrolled. After a baseline season, SLIT or matched placebo are given for 10 months. Symptoms and rescue medication intake are recorded on diary cards from June to October. Skin prick test, specific IgE and IgG4 and precipitins are measured at baseline and at the end of the study. Alternaria spore count is also performed. Primary outcome is the change in symptom score in the active vs placebo group. Secondary outcomes: changes in rescue medication intake, alternaria specific IgE and IgG4, skin prick test reactivity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Grazax | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1, 2
B: Arm Label: SLIT; Type: EXPERIMENTAL; Interventions: Biological: sublingual immunotherapy | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: sublingual immunotherapy; Assigned to Arm(s): SLIT | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: 300 IR; Type: EXPERIMENTAL; Interventions: Drug: 300 IR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 300 IR; Assigned to Arm(s): 300 IR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Birch pollen allergen extract; Type: EXPERIMENTAL; Interventions: Biological: Birch pollen allergen extract | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Birch pollen allergen extract; Assigned to Arm(s): Birch pollen allergen extract

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?
Brief Summary: It is now well recognized that Attention-Deficit/Hyperactivity Disorder (ADHD) is a chronic disorder of childhood that extends into adulthood for many individuals. A number of impairments in daily life functioning have been identified in adults with ADHD, including marital distress, risky driving, and using less effective parenting practices (e.g., Barkley, 2006).

Specifically, some parents with ADHD have been found to use inconsistent discipline, less parental involvement, and less positive reinforcement with their children compared to parents without ADHD (e.g., Chen \& Johnston, 2007; Chronis-Tuscano, Clarke, Rooney, Diaz, \& Pian, 2008). While there is some evidence that stimulant medication improves parental functioning for adults with ADHD, only one study has specifically explored the use of stimulant medication and parenting(Chronis-Tuscano, Seymour, Stine, Jones, Jiles, Rooney, et al., 2008).

The purpose of this study is to explore whether or not the stimulant medication, lisdexamfetamine, improves parent functioning. Measures of parenting behavior, parental psychosocial functioning, and child psychosocial functioning will be collected. It is hypothesized that lisdexamfetamine will be associated with some improvement in these assessments.


Options:
A: Arm Label: stimulant medication; Type: EXPERIMENTAL; Interventions: Drug: lisdexamfetamine | Arm Label: placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: lisdexamfetamine | Intervention Type: DRUG; Name: lisdexamfetamine; Assigned to Arm(s): placebo pill, stimulant medication
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
C: Arm Label: SHP465 12.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SHP465 12.5mg capsules (one capsule daily) | Arm Label: SHP465 37.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SHP465 12.5mg capsules (one capsule daily); Assigned to Arm(s): SHP465 12.5 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily); Assigned to Arm(s): SHP465 37.5 mg
D: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
Brief Summary: Using focus group and cognitive interviews with organ transplant recipients, the investigators developed interactive workbooks: a) prevention by sun protection b) early detection by skin self-examination (SSE). The investigators hypothesis is if the patient learns by acquiring skills in a favorable environment, then the patient may reduce their anxiety, enhance self-efficacy and perform self-management by SSE and sun protection. The investigators also evaluate existing internet sources of primary and secondary prevention of skin cancer for organ transplant recipients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: automated clinical alerts, Other: provider education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: provider education | Intervention Type: OTHER; Name: automated clinical alerts; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: provider education; Assigned to Arm(s): 1, 2
B: Arm Label: TALK Plus; Type: EXPERIMENTAL; Interventions: Behavioral: TALK PLUS | Arm Label: TALK Standard; Type: EXPERIMENTAL; Interventions: Behavioral: TALK Standard | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: TALK PLUS; Assigned to Arm(s): TALK Plus | Intervention Type: BEHAVIORAL; Name: TALK Standard; Assigned to Arm(s): TALK Standard | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Intervention, Behavioral: Placebo | Intervention Type: BEHAVIORAL; Name: Educational Intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): Control, Intervention
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: multidisciplinary predialysis education | Intervention Type: BEHAVIORAL; Name: multidisciplinary predialysis education; Assigned to Arm(s): 2

Answer: C